Post time: Mar-16-2026
Thanks for being so sweet
This GLP-1 and GIP receptor agonist, licensed in the UK for type 2 diabetes, may cause dizziness through reduced fluid intake, blood pressure changes, or low blood sugarparticularly when combined with other diabetes medications
Many patients wonder whether stopping this diabetes medication requires a gradual tapering process
But the compounding of semaglutide is unlikely to end
Thus, as we traverse forward, lets delve deeper, exploring further the individual paths treaded upon by Ozempic and Saxenda, and unwrapping their unique and collective stories within patient management, clinical trials, and healthcare outcomes